XML 24 R9.htm IDEA: XBRL DOCUMENT v3.22.4
Cash, Cash Equivalents and Investments
12 Months Ended
Dec. 31, 2022
Cash, Cash Equivalents and Investments  
Cash, Cash Equivalents and Investments

Note 3 - Cash, Cash Equivalents and Investments

The following table summarizes our cash, cash equivalents, marketable securities, and available-for-sale investments at December 31, 2022 (in thousands):

As of December 31, 2022

    

  

Gross

  

Gross

  

  

 

Cash and

  

  

  

Amortized

Unrealized

Unrealized

 

Cash

Marketable

Short-Term

Long-Term

Cost

Gains

Losses

Fair Value

 

Equivalents

Securities

Investments

Investments

Cash

$

143,744

$

$

$

143,744

$

143,744

$

$

$

Level 1:

 

  

 

  

 

  

 

  

 

  

 

  

 

Money market funds

 

2,669

 

 

2,669

 

2,669

 

 

Agency bonds

 

164,486

6

 

(263)

 

164,229

 

 

 

69,862

94,367

Treasury bills

121,650

18

(3)

121,665

113,100

8,565

Marketable securities

90,000

(50,760)

39,240

 

 

39,240

 

Subtotal

 

378,805

24

 

(51,026)

 

327,803

115,769

39,240

78,427

94,367

Level 2:

State and municipal obligations

4,980

(33)

4,947

4,947

Certificate of deposits

5,002

5,002

5,002

Term deposits

200,000

200,000

25,000

175,000

Corporate bonds

257,422

33

(1,159)

256,296

28,883

168,074

59,339

U.S. Government

30,525

(159)

30,366

30,366

Treasury inflation-protected securities

2,503

(2)

2,501

2,501

Commercial paper

160,241

160,241

40,288

119,953

Subtotal

660,673

33

(1,353)

659,353

94,171

503,342

61,840

Total

$

1,183,222

$

57

$

(52,379)

$

1,130,900

$

353,684

$

39,240

$

581,769

$

156,207

As of December 31, 2022, we had $349.6 million of available-for-sale investments with unrealized losses.

During the year ended December 31, 2021, we acquired 9,000,000 shares of common stock of Cellebrite DI Ltd (“CLBT”) with a fair value of $90.0 million. The CLBT common stock is recorded as marketable securities in the accompanying consolidated balance sheets and its fair value is adjusted every reporting period. Changes in fair value are recorded in the consolidated statement of operations as unrealized gain or (loss) on marketable securities, which is included in interest and other income, net. During the year ended December 31, 2022, we recorded a $32.9 million unrealized loss on marketable securities from our investment in CLBT.

The following table summarizes our cash, cash equivalents, and available-for-sale investments at December 31, 2021 (in thousands):

As of December 31, 2021

  

  

Gross

  

Gross

  

  

 

Cash and

  

  

  

Amortized

Unrealized

Unrealized

 

Cash

Marketable

Short-Term

Long-Term

Cost

Gains

Losses

Fair Value

 

Equivalents

Securities

Investments

Investments

Cash

$

353,488

$

$

$

353,488

$

353,488

$

$

$

Level 1:

 

  

 

  

 

  

 

  

 

  

 

  

 

Money market funds

 

2,844

 

 

2,844

 

2,844

 

 

Agency bonds

 

10,700

4

 

 

10,704

 

 

 

10,704

Marketable securities

90,000

(17,820)

72,180

 

 

72,180

 

Subtotal

 

103,544

4

 

(17,820)

 

85,728

2,844

72,180

10,704

Level 2:

State and municipal obligations

2,570

(5)

2,565

1,400

1,165

Corporate bonds

32,748

1

(276)

32,473

2,406

30,067

Subtotal

35,318

1

(281)

35,038

3,806

31,232

Total

$

492,350

$

5

$

(18,101)

$

474,254

$

356,332

$

72,180

$

14,510

$

31,232

During the year ended December 31, 2021, we sold held-to-maturity securities with a net carrying amount of $165.4 million prior to their maturity.